-transparent.png){kind=logo}
Intravenous gammaglobulin (IVGG) can improve the clinical course of several immune-mediated diseases. We report the first results of such treatment in eight patients with severe Guillain-Barré syndrome (GBS). We observed that IVGG was beneficial in at least some of the patients with severe GBS. These results should be confirmed in a randomized trial.
Related Publications
R P Kleyweg, and
F G van der Meché, and
J Meulstee
May 1993,
No to hattatsu = Brain and development,
R P Kleyweg, and
F G van der Meché, and
J Meulstee
August 1991,
Anales espanoles de pediatria,
R P Kleyweg, and
F G van der Meché, and
J Meulstee
October 1991,
Harefuah,
R P Kleyweg, and
F G van der Meché, and
J Meulstee
December 1988,
Journal of neuroimmunology,
R P Kleyweg, and
F G van der Meché, and
J Meulstee
November 1992,
The New Zealand medical journal,
R P Kleyweg, and
F G van der Meché, and
J Meulstee
March 1998,
Journal of child neurology,
R P Kleyweg, and
F G van der Meché, and
J Meulstee
June 1994,
Annals of neurology,
R P Kleyweg, and
F G van der Meché, and
J Meulstee
June 1993,
Rinsho shinkeigaku = Clinical neurology,
R P Kleyweg, and
F G van der Meché, and
J Meulstee
December 2007,
Klinische Monatsblatter fur Augenheilkunde,
R P Kleyweg, and
F G van der Meché, and
J Meulstee
November 1991,
Lancet (London, England),
